Indofarma Tbk PT
IDX:INAF
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| ID |
|
Indofarma Tbk PT
IDX:INAF
|
390.5B IDR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
964.4B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
572.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
284.4B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
297.7B USD |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
217.3B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
227.3B CHF |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
151.1B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120.9B USD |
Loading...
|
Market Distribution
| Min | -220 730.8% |
| 30th Percentile | 0% |
| Median | 3.7% |
| 70th Percentile | 9.8% |
| Max | 190 521.4% |
Other Profitability Ratios
Indofarma Tbk PT
Glance View
PT Indofarma Tbk is engaged in the pharmaceutical and healthcare businesses. The company is headquartered in Bekasi, Jawa Barat and currently employs 1,095 full-time employees. The company went IPO on 2001-04-17. The firm's business segment based on the products consists of the drug business segment and other medical equipment segment. The medical equipment segment consists of diagnostic and medical equipment. Its business segment based on geographical distribution area covers five regions consisting of Sumatra, Java, Kalimantan, Sulawesi and Bali, West Nusa Tenggara, and East Indonesia. Its products and services include generic drugs, over-the-counter and food, medical devices, non-medical devices and household health products. The firm carries out business activities to produce either alone or under cooperation for finished drug products, such as essential medicines, generic medicines with logos, generic medicines with trade names, traditional medicines, medical equipment, diagnostics, as well as food products, both related to health maintenance and improvement as well as health restoration.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Indofarma Tbk PT is -143.1%, which is above its 3-year median of -152.3%.
Over the last 3 years, Indofarma Tbk PT’s Net Margin has decreased from -9.7% to -143.1%. During this period, it reached a low of -322.5% on Sep 30, 2024 and a high of -9.7% on Aug 30, 2022.
